Why the study?
The review aimed to summarize the state of the art in von Willebrand disease treatment, focusing on specific clinical settings and the use of a VWF concentrate with low FVIII content.
Does von Willebrand factor concentrate with low FVIII content improve management in patients with inherited von Willebrand disease requiring surgical or secondary long-term prophylaxis?
Does von Willebrand factor concentrate with low FVIII content improve management in patients with inherited von Willebrand disease requiring surgical or secondary long-term prophylaxis?
Expert consensus suggests that VWF concentrates with low FVIII content are useful for managing VWD patients at high thrombotic risk or requiring long-term prophylaxis.
Authors
No takes yet. Share an insight, caveat, or question.
May support low-FVIII VWF concentrate use in high-thrombotic-risk VWD; leaves open prospective confirmation before practice change.
Castaman et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: